ישראל - עברית - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

ישראל - עברית - Ministry of Health

j-c health care ltd - daratumumab - תרכיז להכנת תמיסה לאינפוזיה - daratumumab 20 mg / 1 ml - daratumumab

ישראל - עברית - Ministry of Health

j-c health care ltd - daratumumab - תמיסה להזרקה - daratumumab 120 mg / 1 ml - daratumumab

ישראל - עברית - Ministry of Health

novartis israel ltd - ofatumumab - תמיסה להזרקה - ofatumumab 50 mg/ml - ofatumumab

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - polatuzumab vedotin - אבקה להכנת תמיסה מרוכזת לעירוי - polatuzumab vedotin 140 mg/vial

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ofatumumab 20 mg/ml - concentrate for solution for infusion - ofatumumab - treatment of chronic lymphocytic leukaemia (cll) in patients who are refractory to fludarabine and alemtuzumab

ישראל - עברית - Ministry of Health

glaxo smith kline (israel) ltd - ofatumumab 20 mg/ml - concentrate for solution for infusion - ofatumumab - treatment of chronic lymphocytic leukaemia (cll) in patients who are refractory to fludarabine and alemtuzumab

ישראל - עברית - Ministry of Health

promedico ltd - selinexor - טבליה - selinexor 20 mg - selinexor

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - rituximab - תרכיז להכנת תמיסה לאינפוזיה - rituximab 10 mg/ml - rituximab - rituximab - mabthera is indicated for the following indications: * non-hodgkin’s lymphoma (nhl)mabthera is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma.mabthera is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy mabthera is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. mabthera maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll)mabthera in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including mabthera or patients refractory to previous mabthera plu

ישראל - עברית - Ministry of Health

sanofi israel ltd - dupilumab - תמיסה להזרקה - dupilumab 150 mg/ml - dupilumab